3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
31
Lymphoma
19
Neoplasms, Plasma Cell
16
Myelodysplastic Syndromes
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Non-Hodgkin
13
Leukemia, Myeloid, Acute
13
Leukemia
13
Hodgkin Disease
12
Leukemia, Lymphocytic, Chronic, B-Cell
9
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
7
Retinoblastoma
6
Lymphoma, Mantle-Cell
6
Burkitt Lymphoma
6
Myeloproliferative Disorders
5
Immunoglobulin Light-chain Amyloidosis
5
Recurrence
4
Primary Myelofibrosis
4
Ovarian Neoplasms
4
Neuroblastoma
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myelomonocytic, Juvenile
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hematologic Neoplasms
4
Congenital Abnormalities
4
Sezary Syndrome
3
Myelodysplastic-Myeloproliferative Diseases
3
Interventions
Melphalan
1
Lenograstim
1
1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Castrate Resistant Prostate Cancer
×
Melphalan
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled